Target intelligence / Profile preview

Protein tyrosine kinase 2 (PTK2) (PTK2)

Target
PTK2
Molecular classification
Enzyme
01

Overview

Protein tyrosine kinase 2 (PTK2), commonly known as focal adhesion kinase (FAK), is a cytoplasmic non-receptor tyrosine kinase that plays a central role in integrating extracellular signals from integrins and growth factor receptors to regulate cell adhesion, migration, survival, and proliferation. FAK is highly overexpressed and activated in various solid tumors, including ovarian, pancreatic, and lung cancers, where it drives tumor progression, metastasis, and resistance to chemotherapy and targeted therapies. In May 2025, the FDA granted accelerated approval to the combination of the FAK inhibitor defactinib and the RAF/MEK inhibitor avutometinib for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), marking the first approved therapeutic regimen involving a FAK inhibitor. Beyond oncology, FAK is also implicated in fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and inflammatory conditions, making it a highly attractive therapeutic target. Therapeutic strategies targeting FAK include ATP-competitive small-molecule inhibitors, allosteric inhibitors, and proteolysis-targeting chimeras (PROTACs) designed to degrade the protein and block both its kinase and scaffolding functions.

Other names
Focal adhesion kinase 1Focal adhesion kinaseFAKFAK1Protein-tyrosine kinase 2p125FAKpp125FAKFADK 1PPP1R71
02

Mechanism of action

Focal adhesion kinase inhibition and degradation

03

Biological functions

Signal transductionCell migrationCell adhesionCell proliferationApoptosisCell survivalCytoskeletal reorganization
04

Disease associations

CancerPulmonary fibrosisInflammationAcute lung injuryCardiovascular disease
05

Safety considerations

ProteinuriaFatigueDiarrheaNauseaVomitingHypertriglyceridemiaElevated creatine phosphokinase (CPK)RhabdomyolysisOcular toxicities (e.g., vitreoretinal disorders, visual impairment)Skin reactions (e.g., rash, dermatitis acneiform)Off-target PYK2 inhibition (potential hematological/immune effects)
06

Interacting drugs

9 more in the full profile.

07

Biomarkers

KRAS mutationPTK2 gene amplificationFAK phosphorylation (Y397)FAK expression level

Beyond the preview

Go deeper on Protein tyrosine kinase 2 (PTK2) (PTK2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein tyrosine kinase 2 (PTK2) (PTK2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call